BTK and mantle cell lymphoma: Currently, Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and the BCL-2 inhibitor venetoclax are clinical MCL treatment options that produce high response rates and reasonably durable outcomes in this patient population10–12.